Pharmaceutical Executive February 23, 2024
Results of a study conducted by the National Institutes of Health indicate that the Paxlovid prevented a substantial number of hospitalizations associated with COVID-19.
Greater use of Pfizer’s Paxlovid (nirmatrelvir/ritonavir) in high-risk patients infected with COVID-19 could significantly reduce the number of hospitalizations and save billions of dollars in healthcare spending, according to a study by the National Institutes of Health.
The study, which assessed the benefits associated with increased use of Paxlovid to treat COVID-19, found that only 15% of high-risk patients are administered the medication when infected with the virus. Additionally, they discovered that treating 20% of symptomatic patients with Paxlovid over 300 days from January 2022 resulted in significant cost reductions and fewer deaths, specifically during the...
Today's Sponsors
Today's Sponsor